[#DIV28SUPER] Fw: Final Recommendation Statement: Screening for Unhealthy Drug Use

Forwarding on behalf of Jacob Marzalik.

               
---------------------------------------------------------------------------------
William W. Stoops, Ph.D.
email: william.stoops@uky.edu
telephone: (859) 257-5383

Professor
Departments of Behavioral Science, Psychiatry and Psychology
Center on Drug and Alcohol Research
University of Kentucky

Director
Regulatory Knowledge and Support Core-Center for Clinical and Translational Science

Clinical Research Support Office

STATEMENT OF CONFIDENTIALITY
The contents of this e-mail message and any attachments are confidential and are intended solely for the addressee. The information may also be legally privileged. This transmission is sent in trust, for the sole purpose of delivery to the intended recipient. If you have received this transmission in error, any use, reproduction or dissemination of this transmission is strictly prohibited. If you are not the intended recipient, please immediately notify the sender by reply e-mail or at (859) 257-5383 and delete this message and its attachments, if any.

---

From: Marzalik, Jacob <JMarzalik@apa.org>
Sent: Wednesday, June 10, 2020 10:41 AM
To: DIV28SUPER-request@LISTS.APA.ORG <DIV28SUPER-request@LISTS.APA.ORG>
Subject: FW: Final Recommendation Statement: Screening for Unhealthy Drug Use

 

CAUTION: External Sender

Hi,

 

Would you mind forwarding the previous two emails below to Division 28 colleagues for their reference?

 

Many thanks,

Jacob

 

Jacob S. Marzalik, MA

Project Manager, Clinical Practice Guidelines

Practice Transformation and Quality, Practice Directorate

American Psychological Association

  

All APA staff are teleworking until further notice and are experiencing a high volume of inquiries related to COVID-19. For immediate information and resources, visit APA's COVID-19 page for psychologists, health-care workers, and the public.

 

From: Marzalik, Jacob
Sent: Wednesday, June 10, 2020 10:39 AM
To: div28super@lists.apa.org
Cc: Halfond, Raquel <rhalfond@apa.org>
Subject: FW: Final Recommendation Statement: Screening for Unhealthy Drug Use

 

Hello Division 28 colleagues,

 

The U.S. Preventive Services Task Force just released final recommendations and an evidence summary on Screening for Unhealthy Drug Use. A clinician summary is also available on the Task Force website, which provides guidance to primary care clinicians for using the recommendation in practice. See below for more information

 

Please forward to interested colleagues.

 

Thank you.

 

Jacob S. Marzalik, MA

Project Manager, Clinical Practice Guidelines

Practice Transformation and Quality, Practice Directorate

American Psychological Association

 

750 First Street NE, Washington, DC 20002-4242

202-336-5872

 

All APA staff are teleworking until further notice and are experiencing a high volume of inquiries related to COVID-19. For immediate information and resources, visit APA's COVID-19 page for psychologists, health-care workers, and the public.

 

From: Agency for Healthcare Research and Quality (AHRQ) <updates@subscriptions.ahrq.gov>
Sent: Tuesday, June 9, 2020 11:04 AM
To: Marzalik, Jacob <JMarzalik@apa.org>
Subject: Final Recommendation Statement: Screening for Unhealthy Drug Use

 

 

June 9, 2020 Final Recommendation Statement: Screening for Unhealthy Drug Use Final Recommendation Statement: Screening for Unhealthy Drug Use The U.S. Preventive Services Task Force released today a final recommendation statement on screening for unhealthy drug use. That Task Force found that clinicians should ask adults about their drug use and connect people who have a problem to care. More research is needed to make a recommendation for teens. To view the recommendation, the evidence on which it is based, and a summary for clinicians, please go here. The final recommendation statement can also be found in the June 9, 2020 online issue of JAMA. The Final Recommendation Statement Is Available FINAL RECOMMENDATION SUMMARY See the full statement Population Recommendation Grade Adults age 18 years or older The USPSTF recommends screening by asking questions about unhealthy drug use in adults age 18 years or older. Screening should be implemented when services for accurate diagnosis, effective treatment, and appropriate care can be offered or referred. (Screening refers to asking questions about unhealthy drug use, not testing biological specimens.) B Adolescents The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for unhealthy drug use in adolescents. See the "Practice Considerations" section for suggestions for practice regarding the I statement. I WHY THIS MATTERS "The physical, mental, and social effects of drug use can be grave for both individuals and families," says Task Force vice chair Karina Davidson, Ph.D., M.A.Sc. "The good news is that primary care clinicians can help by asking adults about their drug use and providing a connection to treatment and support for those who need it." WHERE WE ARE IN THE PROCESS Draft Research Plan Final Research Plan Draft Recommendation / Draft Evidence Review  Final Recommendation / Evidence Summary

---

This email was sent to jmarzalik@apa.org using GovDelivery Communications Cloud on behalf of: Agency for Healthcare Research and Quality (AHRQ) · 5600 Fishers Lane, Rockville, MD 20857 · 301-427-1364

---

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

[#DIV28SUPER] Message from NIDA Director Nora Volkow on Racially Motivated Violence

Here’s Nora’s latest blog addressing issues of racism and substance use disorder.

 

https://www.drugabuse.gov/about-nida/noras-blog/2020/06/message-director-racially-motivated-violence?utm_source=daRSS&utm_medium=email&utm_campaign=da-researcherdigest

 

Wendy J. Lynch, Ph.D.

Associate Professor of Psychiatry and Neurobehavioral Sciences

President, APA Division 28 (Psychopharmacology and Substance Abuse)

Physical Address: 450 Ray C. Hunt Drive (Aurbach Building), Room G164

Mailing Address: PO Box 801402, Charlottesville, VA 22904-1402

434-243-0580 (office)

434-249-3699 (cell)

 

 

[#DIV28SUPER] Editorial Fellowship Available for Experimental and Clinical Psychopharmacology

Experimental and Clinical Psychopharmacology announces an opening for an Editorial Fellow position, beginning January 1, 2021. The position is open to qualified candidates who hold the rank of Assistant Professor (or equivalent) and will last one year. During this time, the selected Fellow will work closely with the journal's Editor, Dr. William W. Stoops, to develop editorial and publishing proficiency, enrich scientific knowledge and bolster written communication skills. It is anticipated that the Fellow will manage approximately one new manuscript per month. This process will include identifying reviewers, making an editorial decision based on review and shepherding the manuscript through to publication if accepted, all with guidance from Dr. Stoops. The successful candidate will also be expected to participate in monthly meetings with Dr. Stoops to ensure goals are met and problems are identified and addressed. The majority of these meetings will be phone conferences, although in-person meetings at scientific conferences are also possible. Upon successful completion of the fellowship, the Editorial Fellow will become a member of the journal's editorial board. All applications should include the following: 1) an interest statement, 2) a curriculum vitae and 3) three recommendation letters. Application materials are due to Dr. Stoops (william.stoops@uky.edu) on September 1, 2020 at 5 PM Eastern time and should be submitted as a single pdf file. Applications will be reviewed by members of the Experimental and Clinical Psychopharmacology editorial board for strength of the interest statement, research and publishing experience, manuscript review experience and enthusiasm of the recommendation letters. The top candidate will be notified of her/his selection by December 1, 2020. Address any questions to Dr. Stoops at william.stoops@uky.edu.

 

 

               
---------------------------------------------------------------------------------
William W. Stoops, Ph.D.
email: william.stoops@uky.edu
telephone: (859) 257-5383

Professor
Departments of Behavioral Science, Psychiatry and Psychology
Center on Drug and Alcohol Research
University of Kentucky

Director
Regulatory Knowledge and Support Core-Center for Clinical and Translational Science

Clinical Research Support Office

STATEMENT OF CONFIDENTIALITY
The contents of this e-mail message and any attachments are confidential and are intended solely for the addressee. The information may also be legally privileged. This transmission is sent in trust, for the sole purpose of delivery to the intended recipient. If you have received this transmission in error, any use, reproduction or dissemination of this transmission is strictly prohibited. If you are not the intended recipient, please immediately notify the sender by reply e-mail or at (859) 257-5383 and delete this message and its attachments, if any.

[#DIV28SUPER] NIDA Neuroscience Update, May 27, 2020

• Single Cell Opioid Responses in the Context of HIV (SCORCH) Program Expansion: CNS Data Generation for Chronic Opioid, Methamphetamine, and/or Cocaine Exposures (U01 Clinical Trial Not Allowed)
  (RFA-DA-21-019)
  National Institute on Drug Abuse
  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.

• Large scale mapping and/or molecular profiling of ensembles and/or cell-types mediating opioid action in the rodent brain (R01 - Clinical Trial Not Allowed)
  (PAR-20-182)
  National Institute on Drug Abuse
  Application Receipt Date(s): October 30, 2020
• Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)

(Note: COVID-19 research related to substance abuse and substance use disorders  is within scope of this FOA)

National Institute on Drug Abuse

National Cancer Institute

(PAR-19-064)

Application Receipt Date(s): June 8, 2020; October 6, 2020; February 8, 2021; June 8, 2021; October 8, 2021, by 5:00 PM local time of applicant organization

 

• Reminder of Notice of Special Interest (NOSI): NHLBI and NIDA Announce Availability of Administrative Supplements for HEAL Awardees to Address Sleep Impairments in OUD Treatment Response and Recovery Outcomes

(NOT-HL-20-746)

Key Dates
Release Date: March 27, 2020
First Available Due Date: June 01, 2020 
Expiration Date: June 02, 2020

NIDA offers Genotyping to Substance Abuse Disorder Investigators

(NOT-DA-20-041)

Submit requests no later than September 14, 2020

 

• NIDA Center for Genetics Studies offers services to generate high quality induced pluripotent stem cells (iPSC) from people who use substances.

Please direct your request to Jonathan D. Pollock, Ph.D.

 

• Other NIDA Funding Opportunities

 

The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services  TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L   in the message body of the email - You will receive a confirmation email if successful. If you have problems contact jpollock@mail.nih.gov   301-435-1309

 

 

[#DIV28SUPER] Joint Meeting of the Advisory Councils of NIAAA, NIDA, NCI - May 2020

Hello Division 28 Members!

 

As many of you may know, NIDA, NIAAA, and CRAN Advisory Councils met recently. The presentations from NIDA and NIAAA include resources and information related to substance use disorder and COVID-19, as well as other useful information that may be of interest to you including an update on the ABCD study. These presentations are video archived here.

 

Hope you are all doing well.

 

Wendy J. Lynch, Ph.D.

President, APA Division 28 (Psychopharmacology and Substance Abuse)

Associate Professor of Psychiatry and Neurobehavioral Sciences

Physical Address: 450 Ray C. Hunt Drive (Aurbach Building), Room G164

Mailing Address: PO Box 801402, Charlottesville, VA 22904-1402

434-243-0580 (office)

434-249-3699 (cell)

 

[#DIV28SUPER] Wayne State University adds new Endowed Chair in Addiction and Pain Biology - School of Medicine News - Wayne State University

https://today.wayne.edu/medicine/news/2020/04/29/wayne-state-university-adds-new-endowed-chair-in-addiction-and-pain-biology-37132

Congratulations!

Sent from my iPhone
_____________________ div28SUPER@lists.apa.org _____________________
Div28m members #div28 subscribers corner: http://lists.apa.org

[#DIV28SUPER] Anesthesiology is among the highest risk occupations (including death)

Access to agents with abuse potential is a major determinant of abuse liability.

This paper provides remarkable new quantitative evidence. The hazard has been known for decades, and the authors discuss the likelihood of underestimation.

This paper is unusual in that it links professional organization records with potential for under reporting with an independent death registry that records cause of death.

The risk of death in this profession approaches that of the commercial fishing industry.

Perioperative Medicine | April 2020

Substance Use Disorder in Physicians after Completion of Training in Anesthesiology in the United States from 1977 to 2013

Anesthesiology

Newly Published on April 9, 2020.

doi:https://doi.org/10.1097/ALN.0000000000003310


Sent from my iPhone
_____________________ div28SUPER@lists.apa.org _____________________
Div28m members #div28 subscribers corner: http://lists.apa.org